S100A6 protein expression is different in Spitz nevi and melanomas

Modern Pathology

Volumn 16, Issue 5, 2003, Pages 505-511

  Ribé, Adriana ^a   McNutt, N Scott ^a,b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b Department of Obstetrics Gynecology   (United States)

Author keywords

Melanocyte; Melanoma; S100; S100A6; Spindle and epithelloid cell nevus; Spitz nevus

Indexed keywords

CALCYCLIN; MONOCLONAL ANTIBODY;

ARTICLE; CALCIUM SIGNALING; CHROMOSOME 1Q; CONTROLLED STUDY; EPIDERMIS; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; JUVENILE MELANOMA; KERATINOCYTE; MALIGNANT LENTIGO; MELANOCYTE; MELANOCYTIC NEVUS; PRIORITY JOURNAL; PROTEIN EXPRESSION;

CELL COUNT; CELL CYCLE PROTEINS; DIAGNOSIS, DIFFERENTIAL; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEVUS, EPITHELIOID AND SPINDLE CELL; NEVUS, PIGMENTED; S100 PROTEINS; SKIN NEOPLASMS; UP-REGULATION;

EID: 0038485603     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.MP.0000071128.67149.FD     Document Type: Article

References (62)

1. Spitz S. Melanoma of childhood. Am J Pathol 1948;24:591-609.
2. Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of criteria for diagnosis and prognosis. Cancer 1953;6:1-45.
3. Reed RJ, Ichinose H, Clark WH, Mihm MC. Common and uncommon melanocytic nevi and borderline melanomas. Semin Oncol 1975;2:119-47.
4. Paniago-Pereira C, Maize JC, Ackerman AB. Nevus of large spindle and/or epithelioid cells (Spitz nevus). Arch Dermatol 1978;14:1811-23.
5. Weedon D. Borderline melanocytic tumors. J Cutan Pathol 1985;12:266-70.
6. Gown AM, Vogel AM, Hoak D, Gough F, McNutt MA. Monoclonal antibodies specific for melanocytic tumors distinguish subpopulations of melanocytes. Am J Pathol 1986;123:195-203.
7. LeBoit PE, Fletcher HV. A comparative study of Spitz nevus and nodular malignant melanoma using image analysis cytometry. J Invest Dermatol 1987;88:753-7.
8. Colombari R, Bonetti F, Zamboni G, Scarpa A, Marino F, Tomezzoli A. Distribution of melanoma specific antibody (HMB-45) in benign and malignant melanocytic tumors. Virchows Arch 1988;413:17-24.
9. Palazzo JP, Duray PH. Congenital agminated Spitz nevi: immunoreactivity with a melanoma-associated monoclonal antibody. J Cutan Pathol 1988;15:166-70.
10. Smoller BR, McNutt NS, Hsu A. HMB-45 recognizes stimulated melanocytes. J Cutan Pathol 1989;16:49-53.
11. Sun J, Morton TH Jr, Gown AM. Antibody HMB-45 identifies the cells of blue nevi. An immunohistochemical study on paraffin sections. Am J Surg Pathol 1990;14:748-51.
12. Skelton HGI, Smith KJ, Barrett TL, Lupton GP, Graham JH. HMB45 staining in benign and malignant melanocytic lesions. A reflection of cellular activation. Am J Dermatopathol 1991;13:543-50.
13. Soyer HP, Smolle J, Kerl H. Ki67 immunostaining in melanocytic skin tumors. Correlation with histologic parameters and prognostic significance. Am J Dermatopathol 1991;13:196-7.
14. Wood WS, Tron VA. Analysis of HMB-45 immunoreactivity in common and cellular blue nevi. J Cutan Pathol 1991;18:261-3.
15. Lazzaro B, Elder DE, Rebers A, Power L, Herlyn M, Menrad A, et al. Immunophenotyping of compound and Spitz nevi and vertical growth phase melanomas using a panel of monoclonal antibodies reactive in paraffin sections. J Invest Dermatol 1993;100:313s-7s.
16. Tu P, Miyauchi S, Miki Y. Proliferative activities in Spitz nevus compared with melanocytic nevus and malignant melanoma using expression of PCNA/cyclin and mitotic rate. Am J Dermatopathol 1993;15:311-4.
17. De Wit PE, Kerstens HM, Poddighe PJ, Van Muijen GN, Ruiter DJ. DNA in situ hybridization as a diagnostic tool in the discrimination of melanoma and Spitz naevus. J Pathol 1994;173:227-33.
18. Steiner A, Binder M, Mossbacher U, Wolff K, Pehamberger H. Estimation of the volume-weighted mean nuclear volume discriminates Spitz's nevi from nodular malignant melanomas. Lab Invest 1994;70:381-5.
19. Thompson CT. Cytogenetics of cutaneous malignant melanoma. In: LeBoit PE, editor. Pathology: state of arts review. Malignant melanoma and melanocytic neoplasms. 1st ed. Philadelphia: Hanley and Belfus; 1994. p. 401-12.
20. McNutt NS, Urmacher C, Hakimian J, Hoss DM, Lugo J. Nevoid maligna melanoma: morphologic patterns and immunohistochemical reactivity. J Cutan Pathol 1995;22:502-17.
21. Penneys N, Seigfried E, Nahass G, Vogler C. Expression of proliferating cell nuclear antigen in Spitz nevus. J Am Acad Dermatol 1995;32:964-7.
22. Smolle J, Hofmann-Wellenhof R, Soyer HP. Approach to diagnostic image analysis of melanocytic tumors. J Cutan Pathol 1995;22:128-31.
23. Bergman R, Sabo E, Schafer I. Measurement of the maturation parameter by using computer-assisted interactive image analysis may be helpful in the differential diagnosis between compound Spitz nevus and malignant melanoma. Am J Dermatopathol 1996;18:567-70.
24. Lee CS, Pirdas A, Lee MW. Immunohistochemical demonstration of the nm23-H1 gene product in human malignant melanoma and Spitz nevi. Pathology 1996;28:220-4.
25. Vogt T, Stolz W, Glabl A, Abmayr W, Hohenleutner U, Schmoeckel C, et al. Multivariate DNA cytometry discriminates between Spitz nevi and malignant melanomas because large polymorphic nuclei in Spitz are not aneuploid. Am J Dermatol 1996;18:142-50.
26. Bergman R, Lurie M, Kerner H, Killim S, Friedman-Birnbaum R. Mode of c-myc protein expression in Spitz nevi, common melanocytic nevi and malignant melanomas. J Cutan Pathol 1997;24:219-22.
27. Prieto VG, Woodruff JM. Expression of HMB45 antigen in spindle cell melanoma. J Cutan Pathol 1997;24:580-1.
28. McNutt NS. The S100 family of multipurpose calciumbinding proteins. J Cutan Pathol 1998;25:521-9.
29. Bastian BC, Le Boit PE, Pinkel D. Mutations and copy number increase of HRAS in Spitz nevi with distinctive histopathological features. Am J Pathol 2000;157:967-72.
30. Nagasaka T, Lai R, Medeiros LJ, Brynes RK, McCourty A, Harada T, et al. Cyclin D1 overexpression in Spitz nevi: an immunohistochemical study. Am J Dermatopathol 1999;21:115-20.
31. Sprecher E, Bergman R, Meilick A, Kerner H, Manov L, Reiter I, et al. Apoptosis, Fas and Fas-ligand expression in melanocytic tumors. J Cutan Pathol 1999;26:72-7.
32. Wettengel GV, Draeger J, Kiesewetter F, Schell H, Neubauer S, Gebhart E. Differentiation between Spitz nevi and malignant melanoma by interphase fluorescence in situ hybridization. Int J Oncol 1999;14:1177-83.
33. Bastian BC, Wesselmann U, Pinkel D, Le Boit P. Molecular cytogenetic analysis of Spitz nevi shows clear differences to melanoma. J Invest Dermatol 1999;113:1065-9.
34. Bergman R, Azzam H, Sprecher E, Manov L, Munichor M, Friedman-Birnbaum R, et al. A comparative immunohistochemical study of MART-1 expression in Spitz nevi, ordinary melanocytic nevi, and malignant melanomas. J Am Acad Dermatol 2000;42:496-500.
35. Evans MJ, Sanders DS, Grant JH, Blessing K. Expression of Melan-A in Spitz, pigmented spindle cell nevi, and congenital nevi: comparative immunohistochemical study. Pediatr Dev Pathol 2000;3:36-9.
36. Ruhoy SM, Prieto VG, Eliason SL, Grichnik JM, Burchette JL, Shea CR. Malignant melanoma with paradoxical maturation. Am J Surg Pathol 2000;24:1600-14.
37. Tosi P, Miracco C, Santopietro R, Pacenti L, Perotti R, Materno M, et al. Possible diagnostic role of telomerase activity in the differential diagnosis between Spitz naevi and cutaneous malignant melanoma. Br J Dermatol 2000;142:1060-1.
38. Harvell JD, Bastian BC, LeBoit PE. Persistent (recurrent) Spitz nevi: a histopathologic, immunohistochemical, and molecular pathologic study of 22 cases. Am J Surg Pathol 2002;26:654-61.
39. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function and expression. Brain Res Bull 1995;37:417-29.
40. Schafer BW, Heizmann CW. The S100 family of EF-hand calcium-binding proteins: functions and pathology. Trends Biochem Sci 1996;21:134-40.
41. Cochran AJ, Wen DR, Herschman HR, Gaynor RB. Detection of S-100 protein as an aid to the identification of melanocytic tumors. Int J Cancer 1982;15:295-7.
42. Nakajima T, Watanabe S, Sato Y, Kameya T, Shimosato Y, Ishihara K. Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 1982;50:912-8.
43. Gaynor R, Herschman HR, Irie R, Jones P, Morton D, Cochran A. S100 protein: a marker for human malignant melanomas? Lancet 1981;1:869-71.
44. Elder DE, Murphy GF, editors. Melanocytic tumors of the skin. Atlas of tumor pathology. 3rd series. Washington, D.C.: Armed Forces Institute of Pathology; 1991.
45. Casso EM, Grin-Jorgensen CM, Grant-Kels JM. Spitz nevi. J Am Acad Dermatol 1992;27:901-13.
46. LeBoit PE. Simulants of malignant melanoma. A rogue's gallery of melanocytic and nonmelanocytic imposters. In: LeBoit PE, editor. Pathology: state of the art reviews. Vol. 2, No. 2. Malignant melanoma and melanocytic neoplasms. 1st ed. Philadelphia: Hanley and Belfus; 1994. p. 195-258.
47. McCalmont TH. The clinical context: A tool for fine-tuning objective histologic diagnosis of cutaneous pigmented lesions. In: LeBoit PE, editor. Pathology: state of the art reviews. Vol. 2, No. 2. Malignant melanoma and melanocytic neoplasms. 1st ed. Philadelphia: Hanley and Belfus; 1994. p. 143-80.
48. Brinck U, Gabius HJ, Zeng FY, Gerke V, Lazarou D, Zografakis C, et al. Differential expression of calcyclin and its accessible ligands in various types of cutaneous tumors. J Dermatol Sci 1995;10:181-90.
49. Ilg EC, Schafer BW, Heizmann CW. Expression pattern of S100 calcium-binding proteins in human tumors. Int J Cancer 1996;68:325-32.
50. Fullen DR, Headington JT. Factor XIIIa-positive dermal dendritic cells and HDL-DR expression in radial versus vertical growth-phase melanomas. J Cutan Pathol 1998;25:553-8.
51. Donato R. Functional roles of the S100 proteins, calciumbinding proteins of the EF-hand type. Biochim Biophys Acta 1999;1450:191-231.
52. Komatsu K, Kobune-Fujimara Y, Andoh A, Ishiguru S, Hunai H, Suzuki N, et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 2000;83:769-74.
53. Stulik J, Osterreicher J, Koupilova K, Knizek J, Bures J, Jandik P, et al. Differential expression of the Ca2+binding S100A6 protein in normal, preneoplastic and neoplastic colon mucosa. Eur J Cancer 2000;36:1050-9.
54. Stradal TB, Gimona M. Ca (2+)-dependent association of S100A6 (calcyclin) with the plasma membrane and the nuclear envelope. J Biol Chem 1999;274:31593-6.
55. Fullen D, Reed J, Finnerty B, McNutt NS. S100A6 preferentially labels type C nevus cells and nevic corpuscles: additional support for schwannian differentiation of dermal nevi. J Cutan Pathol 2001;28:393-9.
56. Fullen DR, Reed JA, Finnerty B, McNutt NS. S100A6 expression in fibrohistiocytic lesions. J Cutan Pathol 2001;28:229-34.
57. Loftus B, Loh LC, Curran B, Henry K, Leader M. Mac387: its non-specific as a tumour marker or marker of histiocytes. Histopathology 1991;19:251-5.
58. Gabrielsen TO, Brandtzaeg P, Hoel PS, Dale I. Epithelial distribution of a myelomonocytic antigen L1 in relation to cutaneous malignancies and melanocytic naevi. Br J Dermatol 1988;118:59-67.
59. McNutt NS, Finnerty B. S100A protein expression reflects the degree of atypia in nevi with architectural disorder. Virchows Arch 1999;435:311.
60. McNutt NS, Finnerty B. S100A protein expression reflects the grade of atypia in nevi with architectural disorder. J Cutan Pathol 1999;26:459.
61. McNutt NS, Reed JA, Murry T, Finnerty B. The antibody MAC387 detects S100A proteins in keratinocytes adjacent to melanoma in situ. Mod Pathol 1999;12:60.
62. Sherstha P, Muramatsu Y, Kudeken W, Mori M, Takai Y, Ilg EC, et al. Localization of Ca2+-binding S100 proteins in epithelial tumors of the skin. Virchows Arch 1998;432:53-9.